About the latest 2025 price guide for Guanfacine

Guanfacine was originally developed as an antihypertensive drug. Its mechanism of action is to selectively stimulate the central α2A adrenergic receptors and reduce sympathetic nerve tone, thus exerting antihypertensive and sedative effects. In recent years, its more well-known indication is the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents, especially for patients with anxiety, tic disorder or insomnia symptoms. Guanfacine has been included in recommended ADHD treatment regimens in multiple international authoritative guidelines, and the proportion of its extended-release preparations prescribed in European and American countries continues to rise.

Guanfacine extended-release tablets (such as the brand nameIntuniv) are indicated for the treatment of ADHD in children 6 years of age and older. Regarding drug prices, domestic generic drugs of guanfacine have currently been approved for marketing in mainland China. However, due to the short time to market and imperfect channel construction, it may be difficult for ordinary patients to obtain physical drugs in hospitals or pharmacies. According to overseas public information, taking the Japanese original research version as an example, the price of guanfacine in 1mg*100 tablets is roughly between 3,000 and 3,500 yuan. The specific price will be affected by import channels, exchange rate fluctuations and regional policies. It is worth noting that there are currently no generic generic drugs available in overseas markets, so the use of guanfacine requires relying on the original brand drug, and the cost of the drug is relatively high.

Although there is an approval number in China, current market circulation is still relatively limited, and original drugs are obtained through overseas and other means. However, such channels are subject to risks such as policy compliance, drug source stability, and price fluctuations.

In general, guanfacine is widely used worldwide for the treatment of ADHD and hypertension, with clear indications and good safety. It especially shows strong potential in the field of children's mental behavioral disorders. With the gradual advancement of domestic drug registration, it is expected to achieve greater accessibility and medical insurance coverage in the future, helping more patients benefit.

Reference materials:https://go.drugbank.com/drugs/DB01018